# Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

> **NCT01262456** · PHASE3 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 395 (actual)

## Conditions studied

- Nocturia

## Interventions

- **DRUG:** Desmopressin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01262456
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262456, "Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01262456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*